Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
81
CMOPF Quote, Financials, Valuation and Earnings
Last price:
$158.04
Seasonality move
:
11.47%
Day range:
$155.38 - $158.04
52-week range:
$55.00 - $169.90
Dividend yield:
2.85%
P/E ratio:
38.26x
P/S ratio:
13.09x
P/B ratio:
2.32x
Volume:
179
Avg. volume:
422
1-year change:
107.95%
Market cap:
$2.7B
Revenue:
$288.6M
EPS (TTM):
$3.57
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Cosmo Pharmaceuticals NV has -- downside to fair value with a price target of -- per share.
CMOPF vs. S&P 500
-
Over the past 5 trading days, Cosmo Pharmaceuticals NV has underperformed the S&P 500 by -0.92% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cosmo Pharmaceuticals NV does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cosmo Pharmaceuticals NV has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cosmo Pharmaceuticals NV reported revenues of --.
Earnings Growth
-
Cosmo Pharmaceuticals NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cosmo Pharmaceuticals NV reported earnings per share of --.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
13.09x
EV / EBIT:
6.44x
EV / Revenue:
3.71x
PEG ratio (5yr expected):
0.11x
EV / Free cash flow:
6.31x
Price / Operating cash flow:
35.29x
Enterprise value / EBITDA:
5.97x
Gross Profit (TTM):
$145.8M
Return On Assets:
10.72%
Net Income Margin (TTM):
30.15%
Return On Equity:
15.06%
Return On Invested Capital:
13.36%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-02-23 | 2025-02-23 | 2025-02-23 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $284.7M | $284.6M | $309M | $196.8M | -- | |
| Total Assets | $669.7M | $799.4M | $800.7M | $684.1M | -- | |
| Current Liabilities | $19.4M | $24.9M | $217.8M | $40.6M | -- | |
| Total Liabilities | $228.2M | $309.2M | $324.6M | $142.4M | -- | |
| Total Equity | $441.5M | $490.1M | $476.2M | $541.7M | -- | |
| Total Debt | $196.6M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-02-23 | 2025-02-23 | 2025-02-23 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
CMOPF
Sector
Market Cap
$2.7B
$25.5M
Price % of 52-Week High
93.02%
49.47%
Dividend Yield
2.85%
0%
Shareholder Yield
7.72%
-1.77%
1-Year Price Total Return
107.95%
-21.96%
Beta (5-Year)
0.402
0.499
Dividend yield:
2.85%
Annualized payout:
$2.17
Payout ratio:
-103.16%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$155.82
200-day SMA
Buy
Level
$90.22
Bollinger Bands (100)
Buy
Level
82.55 - 142.69
Chaikin Money Flow
Buy
Level
215
20-day SMA
Buy
Level
$153.13
Relative Strength Index (RSI14)
Buy
Level
57.55
ADX Line
Buy
Level
12.26
Williams %R
Neutral
Level
-40.3951
50-day SMA
Buy
Level
$141.12
MACD (12, 26)
Buy
Level
35.08
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
618
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.5733)
Buy
CA Score
(Annual)
Level (2.0554)
Sell
Beneish M-Score
(Annual)
Level (-2.0311)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.5346)
Buy
Piotroski F Score
(Annual)
Level (9)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Stock Forecast FAQ
In the current month, CMOPF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CMOPF average analyst price target in the past 3 months is --.
-
Where Will Cosmo Pharmaceuticals NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cosmo Pharmaceuticals NV share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Cosmo Pharmaceuticals NV?
Analysts are divided on their view about Cosmo Pharmaceuticals NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cosmo Pharmaceuticals NV is a Sell and believe this share price will rise from its current level to --.
-
What Is Cosmo Pharmaceuticals NV's Price Target?
The price target for Cosmo Pharmaceuticals NV over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CMOPF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cosmo Pharmaceuticals NV is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CMOPF?
You can purchase shares of Cosmo Pharmaceuticals NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cosmo Pharmaceuticals NV shares.
-
What Is The Cosmo Pharmaceuticals NV Share Price Today?
Cosmo Pharmaceuticals NV was last trading at $158.04 per share. This represents the most recent stock quote for Cosmo Pharmaceuticals NV. Yesterday, Cosmo Pharmaceuticals NV closed at $158.04 per share.
-
How To Buy Cosmo Pharmaceuticals NV Stock Online?
In order to purchase Cosmo Pharmaceuticals NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CMOPF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CMOPF
Sector
P/E ratio
38.26x
23.41x
PEG ratio
0.11x
-0.01x
P/B ratio
2.32x
1.78x
Price / LTM sales
13.09x
1.56x
Growth Metrics
CMOPF
Sector
Revenue growth
--
3.51%
Earnings growth
--
9.95%
Revenue (5-year growth)
32.77%
6.45%
Earnings forecast
--
-$0.19
Profitability
CMOPF
Sector
Profitability FY 2024
$237.5M
$2.6M
Return on invested capital
13.36%
-33.25%
Return on assets
10.72%
-29.68%
Return on equity
15.06%
-38.71%
Earnings Date
Last Earnings Date
Jul
23
Next Earnings Date
Mar
9
Estimated Next Earnings Date
Oct
22
Balance Sheet
CMOPF
Sector
Total cash
$143M
$25M
Short term investments
$102.7M
$24M
Total assets
$669.7M
$71.9M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
